NEW YORK (Reuters) – As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics.
Since leaving the FDA in April, Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates, one of the country’s largest venture capital firms where he worked prior to his time in government.
Image: FILE PHOTO: FDA Commissioner Scott Gottlieb speaks during an interview with Reuters in New York City, U.S., November 26, 2018. REUTERS/Brendan McDermid/File Photo -https://www.reuters.com
{iframe}https://www.reuters.com/article/us-healthcare-gottlieb-investing/ex-fda-chief-gottlieb-sees-investment-opportunity-in-unloved-antibiotics-idUSKBN1X82LR{/iframe}